Area of research
Physiology · Psychiatry and Mental health
Research interest
Research interests include Alzheimer's disease research and treatments, Dementia and Cognitive Impairment Research, Functional Brain Connectivity Studies, and Medical Imaging Techniques and Applications.
Plasma phospho-tau217 for Alzheimer’s disease diagnosis in primary and secondary care using a fully automated platform
Frequency and Clinical Outcomes Associated With Tau Positron Emission Tomography Positivity
Tau PET positivity in individuals with and without cognitive impairment varies with age, amyloid-β status, APOE genotype and sex
Machine learning prediction of tau‐PET in Alzheimer's disease using plasma, MRI, and clinical data
Connectivity as a universal predictor of tau progression in atypical Alzheimer’s disease
Tau Positron Emission Tomography for Predicting Dementia in Individuals With Mild Cognitive Impairment
Harmonizing tau positron emission tomography in Alzheimer's disease: The CenTauR scale and the joint propagation model
Head‐to‐Head Comparison of Tau and Amyloid Positron Emission Tomography Visual Reads for Differential Diagnosis of Neurodegenerative Disorders: An International, Multicenter Study
Plasma Biomarker Strategy for Selecting Patients With Alzheimer Disease for Antiamyloid Immunotherapies
The α-synuclein PET tracer [18F] ACI-12589 distinguishes multiple system atrophy from other neurodegenerative diseases
Determinants of cognitive and brain resilience to tau pathology: a longitudinal analysis
Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline
Four distinct trajectories of tau deposition identified in Alzheimer’s disease
Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer’s disease
Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease
Early stages of tau pathology and its associations with functional connectivity, atrophy and memory
Mild behavioral impairment and its relation to tau pathology in preclinical Alzheimer’s disease
A multicenter comparison of [18F]flortaucipir, [18F]RO948, and [18F]MK6240 tau PET tracers to detect a common target ROI for differential diagnosis
Sex differences in off-target binding using tau positron emission tomography
Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders
Spread of pathological tau proteins through communicating neurons in human Alzheimer’s disease
Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer’s disease
Functional brain architecture is associated with the rate of tau accumulation in Alzheimer’s disease
Untangling the association of amyloid-β and tau with synaptic and axonal loss in Alzheimer’s disease
Assessment of Demographic, Genetic, and Imaging Variables Associated With Brain Resilience and Cognitive Resilience to Pathological Tau in Patients With Alzheimer Disease
The impact of demographic, clinical, genetic, and imaging variables on tau PET status
Derivation and utility of an Aβ-PET pathology accumulation index to estimate Aβ load
Distinct tau PET patterns in atrophy‐defined subtypes of Alzheimer's disease
Predicting diagnosis and cognition with <sup>18</sup>F‐AV‐1451 tau PET and structural MRI in Alzheimer's disease
Amyloid and tau accumulate across distinct spatial networks and are differentially associated with brain connectivity